Go Pro

HC Wainwright's Rating of Telix Pharmaceuticals on 7/28/2026

On July 28, 2026, HC Wainwright updated its outlook on Telix Pharmaceuticals (OTCMKTS:TLPPF) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
7/28/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Reiterated Rating
7/28/2026
Ocean Power Technologies, Inc. stock logo
OPTT
Ocean Power Technologies
Reiterated Rating
7/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Reiterated Rating
7/28/2026
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
Reiterated Rating
7/28/2026
Vericel Corporation stock logo
VCEL
Vericel
Reiterated Rating
7/28/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Boost Price Target
More Ratings From HC Wainwright